Gregory Verhoest
Overview
Explore the profile of Gregory Verhoest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
1097
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Viegas V, Freton L, Richard C, Haudebert C, Khene Z, Hascoet J, et al.
World J Urol
. 2024 Mar;
42(1):172.
PMID: 38506927
Purpose: To compare the outcomes of patients undergoing robotic YV plasty for bladder neck contracture (BNC) vs. vesico-urethral anastomotic stricture (VUAS). Methods: A retrospective study included male patients who underwent...
2.
Courboin E, Mathieu R, Panetta V, Mjaess G, Diamand R, Verhoest G, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835425
Background: For non-muscle-invasive bladder cancer (NMIBC) requiring radical surgery, limited data are available comparing robotic-assisted radical cystectomy with intracorporeal urinary diversion (iRARC) to open radical cystectomy (ORC). The objective of...
3.
Branger N, Bladou F, Verhoest G, Knipper S, Robert G, Bernhard J, et al.
World J Urol
. 2023 Jul;
41(9):2405-2411.
PMID: 37507528
Purpose: To evaluate the feasibility, safety, and early oncologic outcomes after post-chemotherapy robot-assisted retroperitoneal lymph node dissection (PC-RARPLND) for metastatic germ cell tumors (mGCT). Methods: We retrospectively analyzed patients from...
4.
Lebret T, Paoletti X, Pignot G, Roumiguie M, Colombel M, Savareux L, et al.
World J Urol
. 2023 Jul;
41(9):2381-2388.
PMID: 37480491
Purpose: Cytology and cystoscopy, the current gold standard for diagnosing urothelial carcinomas, have limits: cytology has high interobserver variability with moderate or not optimal sensitivity (particularly for low-grade tumors); while...
5.
Poinard F, Bessede T, Barrou B, Drouin S, Karam G, Branchereau J, et al.
Clin Transplant
. 2023 May;
37(9):e14998.
PMID: 37138463
Systematic screening for prostate cancer is widely recommended in candidates for renal transplant at the time of listing. There are concerns that overdiagnosis of low-risk prostate cancer may result in...
6.
Sarkis J, Diamand R, Aoun F, Assenmacher G, Assenmacher C, Verhoest G, et al.
Minerva Urol Nephrol
. 2023 Feb;
75(1):50-58.
PMID: 36800680
Background: Blood transfusions (BT) have been associated with adverse oncologic outcomes in multiple malignancies including open radical cystectomy (ORC) for urothelial carcinoma of the bladder (UCB). Robot-assisted radical cystectomy (RARC)...
7.
Szabla N, Matillon X, Calves J, Branchereau J, Champy C, Neuzillet Y, et al.
Urology
. 2022 Oct;
171:152-157.
PMID: 36243142
Objective: To analyze de novo graft carcinoma characteristics from our updated national multicentric retrospective cohort. Methods: Thirty-two transplant centers have retrospectively completed the database. This database concerns all kidney graft...
8.
Mjaess G, Diamand R, Aoun F, Assenmacher G, Assenmacher C, Verhoest G, et al.
Eur J Surg Oncol
. 2022 Aug;
49(8):1511-1518.
PMID: 35970622
Background: Robotic-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) is surging worldwide. Aim of the study was to perform a multicentric cost-analysis of RARC by comparing the gross cost...
9.
Laukhtina E, Boehm A, Peyronnet B, Bravi C, Batista da Costa J, Soria F, et al.
World J Urol
. 2022 May;
40(7):1689-1696.
PMID: 35596017
Introduction: The optimal management of the urethra in patients planned for radical cystectomy (RC) remains unclear. We sought to evaluate the impact of urethrectomy on perioperative and oncological outcomes in...
10.
Kammerer-Jacquet S, Gandon C, Dugay F, Laguerre B, Peyronnet B, Mathieu R, et al.
Histopathology
. 2022 May;
81(2):228-238.
PMID: 35562857
Aims: First described in 2014, renal cell carcinoma (RCC) with TFEB amplification (6p21) is a rare molecular subgroup whose diagnosis is challenging. The prognosis and therapeutic implications remain unclear. Methods:...